NCT02342041View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

August 31, 2015

Conditions
Cognitive Disorders
Interventions
DRUG

SUVN-G3031

DRUG

Placebo

Trial Locations (1)

66211

Quintiles, Overland Park

All Listed Sponsors
lead

Suven Life Sciences Limited

INDUSTRY

NCT02342041 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects | Biotech Hunter | Biotech Hunter